Bringing Order to the Glutamate Chaos in Schizophrenia

Recent genetic linkage studies complement the existing evidence that implicates abnormalities in NMDA receptor-mediated neurotransmission in the pathophysiology of schizophrenia. At the same time, advances in our understanding of the complex mechanisms that modulate the function of NMDA receptors suggest several novel sites for pharmacological manipulation of these receptors. This presents exciting opportunities for rational rather than serendipitous discovery of therapeutics for schizophrenia.

[1]  P. Slater,et al.  Frontal Cortical and Left Temporal Glutamatergic Dysfunction in Schizophrenia , 1989, Journal of neurochemistry.

[2]  Susumu Tonegawa,et al.  Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Bita Moghaddam,et al.  Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders , 2002, Biological Psychiatry.

[4]  P. Conn,et al.  Metabotropic Glutamate Subtype 5 Receptors Modulate Locomotor Activity and Sensorimotor Gating in Rodents , 2003, Journal of Pharmacology and Experimental Therapeutics.

[5]  J. Kemp,et al.  Positive allosteric modulators of metabotropic glutamate 1 receptor: Characterization, mechanism of action, and binding site , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Kennedy,et al.  N‐methyl‐d‐aspartate receptor NR1 subunit gene (GRIN1) in schizophrenia: TDT and case‐control analyses , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[7]  R. Straub,et al.  Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. , 2002, American journal of human genetics.

[8]  Paul J. Harrison,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Genes for Schizophrenia? Recent Findings and Their Pathophysiological Implications , 2022 .

[9]  P. Sham,et al.  Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Streichenwein Sm,et al.  Am J Psychiatry , 1996 .

[11]  Hong Wang,et al.  Dopamine D2 receptors are present in prefrontal cortical afferents and their targets in patches of the rat caudate‐putamen nucleus , 2002, The Journal of comparative neurology.

[12]  D. Javitt.  Glycine modulators in schizophrenia. , 2002, Current opinion in investigational drugs.

[13]  Marc G Caron,et al.  Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia , 1999, Cell.

[14]  P. Conn,et al.  RGS4 Inhibits Signaling by Group I Metabotropic Glutamate Receptors , 1998, The Journal of Neuroscience.

[15]  B. Moghaddam,et al.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.

[16]  C. Tamminga,et al.  Effects of Ketamine in Normal and Schizophrenic Volunteers , 2001, Neuropsychopharmacology.

[17]  K. Davis,et al.  Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. , 2003, The American journal of psychiatry.

[18]  B. Devlin,et al.  Association and linkage analyses of RGS4 polymorphisms in schizophrenia. , 2002, Human molecular genetics.

[19]  H. Stefánsson,et al.  Neuregulin 1 and susceptibility to schizophrenia. , 2002, American journal of human genetics.

[20]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[21]  Hans Forssberg,et al.  Selective up-regulation of dopamine D1 receptors in dendritic spines by NMDA receptor activation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Tamara Hershey,et al.  Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis , 1999, Neuropsychopharmacology.

[23]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[24]  J. Coyle,et al.  Ionotropic glutamate receptors as therapeutic targets in schizophrenia. , 2002, Current drug targets. CNS and neurological disorders.

[25]  S. Hyman,et al.  What Are the Right Targets for Psychopharmacology? , 2003, Science.

[26]  Y. Fukumaki,et al.  Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia , 2003, Psychiatric genetics.

[27]  Stephan Heckers,et al.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. , 2003, Pharmacology & therapeutics.